AC Immune Holds Annual General Meeting of Shareholders
24 juin 2022 16h30 HE
|
AC Immune SA
LAUSANNE, Switzerland, June 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
16 juin 2022 01h00 HE
|
AC Immune SA
Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease Numerical differences...
AC Immune to Present at the 2022 Jefferies Healthcare Conference
31 mai 2022 07h30 HE
|
AC Immune SA
LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
AC Immune CEO Andrea Pfeifer Receives Aenne Burda Award
17 mai 2022 09h00 HE
|
AC Immune SA
LAUSANNE, Switzerland, May 17, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology
09 mai 2022 11h00 HE
|
AC Immune SA
First study of an anti-Abeta vaccine in people living with Down syndrome (DS) Immune response and Alzheimer’s disease (AD) biomarkers showed positive impact of ACI-24 first generation vaccine ...
AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update
28 avr. 2022 07h30 HE
|
AC Immune SA
Two clinical readouts delivered in Q1; five more expected by year-end Interim data from the Phase 1b/2a trial of ACI-35.030 confirm the favorable safety and potent immunogenicity of this...
AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference
27 avr. 2022 07h55 HE
|
AC Immune SA
LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
AC Immune Reports Changes to Senior Management
08 avr. 2022 07h30 HE
|
AC Immune SA
Howard Donovan appointed Chief HR Officer, joins executive committee Joerg Hornstein, CFO, will leave to pursue new role Chris Roberts promoted to Vice President, Finance and appointed Interim CFO ...
AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases
30 mars 2022 07h58 HE
|
AC Immune SA
a-syn PET tracer, ACI-12589, clinically validated in MSA, potentially enables accelerated development of targeted therapeutics and additional a-syn diagnostics Another first for validated...
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
22 mars 2022 07h30 HE
|
AC Immune SA
Seven clinical data readouts expected in 2022Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in...